Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RESTORE (Raptiva (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-Label, Multi-Centre, Phase IV Study of Subcutaneously Administered Raptiva (Efalizumab) in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Treatment With Raptiva.

Next Previous
Search
Trial Profile

RESTORE (Raptiva (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-Label, Multi-Centre, Phase IV Study of Subcutaneously Administered Raptiva (Efalizumab) in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Treatment With Raptiva.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efalizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms RESTORE
  • Sponsors EMD Serono; Merck KGaA

    • Most Recent Events

    • 22 Dec 2009 Planned end date changed from 1 May 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Mar 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top